40 To make these observations more relevant to the NICM population, the MOCHA trial showed a trend towards greater efficacy of carvedilol on left ventricular function in ACE inhibitor‐treated HF patients with NICM compared with ICM. 31 These data suggest that ACE inhibition prevents further remodelling (as previously demonstrated in numerous studies following patients after myocardial infarction), although it may not drive the reversal of such a process in developed HF.
← all excerpts
Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy.
1
—
—